Tempus IHC logistics overview (powered by NeoGenomics)

Tempus offers add-on IHC testing to provide additional insights to help inform your patient care.

Clinical Guideline Recommended

Tempus offers IHC tests that are recommended in clinical guidelines for several cancer types and may be ordered for other cancer types at the clinician’s discretion.

- **FOLR1 (FRα) (powered by NeoGenomics)**
  
  Epithelial Ovarian Cancer (EOC): Recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.¹

- **HER2 with reflex to ERBB2 FISH testing** (powered by NeoGenomics)
  
  Breast: Recommended for all new primary or newly metastatic breast cancers.²
  
  - Reflex to FISH with IHC score of 2+.³
  
  Gastric: Recommended for all gastric cancer patients at the time of diagnosis if metastatic disease is documented or suspected.⁴
  
  - Reflex to FISH with IHC score of 2+.⁴

Other Cancer Specimens: IHC scored according to ASCO/CAP gastric guidelines, no reflex to FISH available.

Specimen Requirements for Pathology

All tissue samples are sent to Tempus, where they will be cut (if needed) and slides will be sent to NeoGenomics for IHC testing.

Send one Tempus tissue kit for both xT/xR and IHC testing.

**FOLR1 (FRα) IHC**

Three to four (3-4) unstained slides cut at 4 microns is preferred, 5 microns acceptable. Minimum of 100 tumor cells needed to interpret staining.

**HER2 IHC**

Six to seven (6-7) unstained slides cut at 4 microns is preferred, 5 microns acceptable. Minimum of 100 tumor cells needed to interpret staining.

**HER2 IHC only**

Three to four (3-4) unstained slides cut at 4 microns is preferred, 5 microns acceptable. Minimum of 100 tumor cells needed to interpret staining.

**FFPE Block (preferred collection method) or FFPE Slides. Use positively-charged, unbaked slides and 10% NBF fixative (no decalcified specimens)**

Ordering & Reporting

Flexible ordering options are available via online ordering through Tempus Hub or paper requisition.

Available as add-on tests to xT solid tumor DNA seq or xR RNA seq.

Results from Tempus are expected within 2 days of NeoGenomics receiving the specimen.¹

In the event of an insufficient tissue, you will receive a TNP (tissue not processed) or QNS (quality not sufficient) report from Tempus on behalf of NeoGenomics.


We help provide access to our tests for patients in financial need. Patients can complete the financial assistance application online at access.tempus.com or call 800.739.4137 to speak to a member of our team.

If you have any questions on our comprehensive portfolio please contact your Tempus Representative or email support@tempus.com

Learn more at TEMPUS.COM